AbbVie, Inc. (ABBV)
256.42
+0.94
(+0.37%)
USD |
NYSE |
Aug 31, 16:00
257.22
+0.80
(+0.31%)
Pre-Market: 07:43
AbbVie Research and Development Expense (Annual) : 8.249B for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 8.249B |
| December 31, 2024 | 8.315B |
| December 31, 2023 | 7.038B |
| December 31, 2022 | 6.487B |
| December 31, 2021 | 6.98B |
| December 31, 2020 | 6.173B |
| December 31, 2019 | 5.377B |
| December 31, 2018 | 5.229B |
| December 31, 2017 | 5.007B |
| Date | Value |
|---|---|
| December 31, 2016 | 4.226B |
| December 31, 2015 | 4.101B |
| December 31, 2014 | 3.297B |
| December 31, 2013 | 2.84B |
| December 31, 2012 | 2.596B |
| December 31, 2011 | 2.503B |
| December 31, 2010 | 2.369B |
| December 31, 2009 | 1.707B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Biogen, Inc. | 1.481B |
| Gilead Sciences, Inc. | 5.688B |
| Regeneron Pharmaceuticals, Inc. | 5.306B |
| Amgen, Inc. | 6.974B |
| REGENXBIO, Inc. | 212.68M |